Get the Daily Brief
Latest Biotech News
Solid licenses AAV‑SLB101 as AAV field readies next‑gen vectors
Solid Biosciences granted Andelyn Biosciences a non‑exclusive worldwide license to use Solid’s next‑generation capsid AAV‑SLB101, intended to enhance skeletal muscle and cardiac tropism while...
miRNA moves from wearables to exosomes: two new sensing and delivery advances
Two distinct advances spotlight microRNA’s dual role as a biomarker and therapeutic handle. Researchers reported engineered NK‑92 cell exosomes delivering miR‑124 that suppressed breast cancer...
AI predicts drug mechanisms and prioritizes molecules — DeepTarget, Terray unveil tools
Two computational advances aim to narrow the gap between in‑silico predictions and actionable drug development. Sanford Burnham and NIH teams released DeepTarget, which integrates drug and genetic...
Rapid diagnostics advance: Ocean Dx sepsis test and WHO clearance for BD HPV assay
A rapid assay from Ocean Dx reported 100% sensitivity and specificity versus blood culture in an early evaluation, detecting >1,000 bacterial species directly from whole blood and delivering...
Big biotech and VC cash returns: Artios $115M and Sofinnova’s €650M close
Investment momentum surfaced across early and mid‑stage biotech: Artios closed an oversubscribed $115 million Series D to advance its DNA damage response portfolio after positive Phase I/IIa data...
J&J pays $3.05B for Halda... buys new anti‑resistance cancer platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to secure HLD‑0915 and the company’s RIPTAC "hold-and-kill" platform. The deal follows Halda’s phase 1/2 readout...
Ziihera tops trastuzumab: Phase 3 HERIZON-GEA‑01 posts PFS, OS gains
Zymeworks and partners Jazz Pharmaceuticals and BeOne announced positive topline results from the Phase 3 HERIZON‑GEA‑01 trial: zanidatamab (Ziihera) plus chemotherapy improved progression‑free...
Nuvalent’s ALK inhibitor posts durable responses — FDA path opens
Nuvalent released Phase 1/2 data for neladalkib in ALK‑positive lung cancer showing objective responses in patients who progressed on prior ALK inhibitors, with a reported overall response rate...
Solve Therapeutics raises $120M — ADC push lands Merck support
Solve Therapeutics closed a $120 million financing to advance its antibody‑drug conjugate (ADC) portfolio for solid tumors, citing backing from strategic pharma investors including Merck. The...
Artios closes $115M Series D — DNA damage repair programs advance
DNA damage response specialist Artios Ltd. raised $115 million in an oversubscribed Series D round to advance its first‑in‑class DDR programs after delivering encouraging Phase 1/IIa data for its...
Sofinnova closes €650M fund... extends early‑stage life‑science capital
Sofinnova Partners closed its Capital XI fund at €650 million (about $750 million), surpassing target and committing more capital to early‑stage biotech and medtech companies. Firm partners said...
Stem cell transplant restores hand function in monkeys... major translational step
A Nature Biotechnology report described extensive restoration of forelimb function in rhesus monkeys after transplanting human embryonic stem cell‑derived spinal cord neural stem cells...
Fecal exfoliome sequencing (Foli‑seq) — noninvasive gut transcriptomics for IBD
Columbia University researchers published a method called Foli‑seq (fecal exfoliome sequencing) in Nature Biotechnology that amplifies host transcripts from exfoliated gut cells in stool to...
Roche’s Axelios 1 previews fast cancer genomics — early data promising
Roche showcased early-access data from its new Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at AMP, with comparisons to Illumina NovaSeq that showed high concordance for tumor‑normal...
Thermo Fisher touts next‑day CGP on Genexus — Oncomine assay trimmed to 24‑hour TAT
Thermo Fisher presented multicenter validation data for its Oncomine Comprehensive Assay Plus on the automated Ion Torrent Genexus system at AMP, arguing the amplicon‑based CGP can deliver results...
J&J buys Halda for $3.05B – adds anti‑resistance RIPTAC platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to secure Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915....
Zanidatamab phase 3 win: Zymeworks and Jazz push HER2 standard
Zymeworks and Jazz Pharmaceuticals announced positive topline results from the Phase 3 HERIZON‑GEA‑01 trial evaluating zanidatamab (Ziihera) in first‑line HER2‑positive locally advanced or...
Merck to buy Cidara for $9.2B: bets on long‑acting influenza prevention
Merck announced an agreement to acquire Cidara Therapeutics for roughly $9.2 billion to add CD388, a long‑acting antiviral designed for seasonal and pandemic influenza prevention. CD388 couples a...
Sofinnova closes €650M fund – fresh capital for early‑stage biotech
Sofinnova Partners closed its Capital XI flagship fund at €650 million (about $750 million), exceeding its initial target and earmarked for early‑stage biopharma and medtech investments. The firm...
Artios raises $115M – DNA damage repair programs get cash
Artios Pharma closed an oversubscribed $115 million Series D to accelerate its DNA damage response (DDR) portfolio after delivering positive Phase I/IIa signals for lead programs. The financing...